Literature DB >> 24718680

Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway.

Hai-Rong Ma1, Jie Wang2, Yiu-Fai Chen3, Hua Chen1, Wei-Shan Wang4, Haji Akber Aisa5.   

Abstract

Icariin (ICA) and icaritin (ICT), with a similar structure to genistein, are the important bioactive components of the genus Epimedium, and regulate many cellular processes. In the present study, using the estrogen receptor (ER)-negative breast cancer cell line, SKBr3, as a model, we examined the hypothesis that ICA and ICT at low concentrations stimulate SKBr3 cell proliferation in vitro through the functional membrane, G protein‑coupled estrogen receptor 1 (GPER1), mediated by the epithelial growth factor receptor (EGFR)‑mitogen-activated protein kinase (MAPK) signaling pathway. MTT assay revealed that ICA and ICT at doses of 1 nM to 1 µM markedly stimulated SKBr3 cell proliferation in a dose-dependent manner. The ICA- and ICT-stimulated cell growth was completely suppressed by the GPER1 antagonist, G-15, indicating that the ICA‑ and ICT-stimulated cell proliferation was mediated by GPER1 activation. Semi-quantitative RT-PCR analysis revealed that treatment with ICA and ICT enhanced the transcription of c-fos, a proliferation-related early gene. The ICA- and ICT-stimulated mRNA expression was markedly attenuated by G-15, AG-1478 (an EGFR antagonist) or PD98059 (a MAPK inhibitor). Our data also demonstrated that ICA and ICT increased the phosphorylation of ERK1/2. The ICA- and ICT-stimulated ERK1/2 phosphorylation was blocked by pre-treatment of the cells with G-15 and AG-1478 or PD 98059. Flow cytometric analysis confirmed that the ICA- and ICT-stimulated SKBr3 cell proliferation involved the GPER1-mediated modulation of the EGFRMAPK signaling pathway. To the best of our knowledge, our current findings demonstrate for the first time that ICA and ICT promote the progression of ER-negative breast cancer through the activation of membrane GPER1.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24718680     DOI: 10.3892/ijmm.2014.1722

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  7 in total

Review 1.  GPER-novel membrane oestrogen receptor.

Authors:  Margaret A Zimmerman; Rebecca A Budish; Shreya Kashyap; Sarah H Lindsey
Journal:  Clin Sci (Lond)       Date:  2016-06-01       Impact factor: 6.124

2.  The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer.

Authors:  Nitin T Telang; Gou Li; Meena Katdare; Daniel W Sepkovic; H Leon Bradlow; George Y C Wong
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

3.  Current update on anticancer effects of icariin: A journey of the last ten years.

Authors:  Mukta Gupta; Yachana Mishra; Vijay Mishra; Murtaza M Tambuwala
Journal:  EXCLI J       Date:  2022-04-06       Impact factor: 4.022

4.  Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer.

Authors:  M-H Lü; B Tang; S Zeng; C-J Hu; R Xie; Y-Y Wu; S-M Wang; F-T He; S-M Yang
Journal:  Oncogene       Date:  2015-11-09       Impact factor: 9.867

5.  Icaritin enhances mESC self-renewal through upregulating core pluripotency transcription factors mediated by ERα.

Authors:  Wing Pui Tsang; Fengjie Zhang; Qiling He; Waijiao Cai; Jianhua Huang; Wai Yee Chan; Ziyin Shen; Chao Wan
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

6.  Icariin induces cell differentiation and cell cycle arrest in mouse melanoma B16 cells via Erk1/2-p38-JNK-dependent pathway.

Authors:  Dan Wang; Wenjuan Xu; Xiaoyu Chen; Jichun Han; Lina Yu; Caixia Gao; Wenjin Hao; Xiaona Liu; Qiusheng Zheng; Defang Li
Journal:  Oncotarget       Date:  2017-08-10

7.  Anti-myeloma Effects of Icariin Are Mediated Through the Attenuation of JAK/STAT3-Dependent Signaling Cascade.

Authors:  Young Yun Jung; Jong Hyun Lee; Dongwoo Nam; Acharan S Narula; Ojas A Namjoshi; Bruce E Blough; Jae-Young Um; Gautam Sethi; Kwang Seok Ahn
Journal:  Front Pharmacol       Date:  2018-05-30       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.